Similar articles

• Sirolimus: mammalian target of rapamycin inhibitor to prevent kidney rejection.

  Cowan PA, Heizer KE. Cowan PA, et al. Nephrol Nurs J. 2000 Dec;27(6):623-5. Nephrol Nurs J. 2000. PMID: 16649344 Review.
• [Immunosuppression with sirolimus so donor kidneys survive longer].

  [No authors listed] [No authors listed] MMW Fortschr Med. 2004 Aug 5;146(31-32):46-7. MMW Fortschr Med. 2004. PMID: 15529711 German. No abstract available.
• [Everolimus: immunosuppression with antilymphoproliferative therapy].

  Pascual J. Pascual J. Nefrologia. 2004;24(2):112-23. Nefrologia. 2004. PMID: 15219086 Review. Spanish. No abstract available.
• Sirolimus for solid organ transplantation in children.

  Gupta P, Kaufman S, Fishbein TM. Gupta P, et al. Pediatr Transplant. 2005 Jun;9(3):269-76. doi: 10.1111/j.1399-3046.2005.00305.x. Pediatr Transplant. 2005. PMID: 15910380
• A retrospective study of conversion from tacrolimus-based to sirolimus-based immunosuppression in orthotopic liver transplant recipients.

  Yu S, He X, Yang L, Ma Y, Zhu X, Ju W, Huang J. Yu S, et al. Exp Clin Transplant. 2008 Jun;6(2):113-7. Exp Clin Transplant. 2008. PMID: 18816237